These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19423283)

  • 1. [About radio-opaque appearance of a phosphate binder, lanthanum carbonate].
    Montagnac R; Schillinger F
    Presse Med; 2010 Apr; 39(4):522-3. PubMed ID: 19423283
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V; Damment SJ; Henderson RA
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radio-opaque fecal impaction and pseudo-occlusion in a dialyzed patient taking lanthanum carbonate.
    Muller C; Muller S; Sissoko A; Klein A; Faller B; Chantrel F
    Hemodial Int; 2012 Oct; 16(4):556-8. PubMed ID: 22118504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radiographic characteristics of lanthanum carbonate absorption].
    Vrigneaud L; Lefèbvre D; Daem AO; Lemaitre V
    Nephrol Ther; 2008 Apr; 4(2):111-3. PubMed ID: 18243834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radiographic disappearance of lanthanum].
    Pastori G
    G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
    Ohtake T; Kobayashi S; Oka M; Furuya R; Iwagami M; Tsutsumi D; Mochida Y; Maesato K; Ishioka K; Moriya H; Hidaka S
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):439-46. PubMed ID: 23615577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radio-opaque appearance of lanthanum carbonate in a patient with chronic renal failure.
    Pafcugová J; Horácková M; Hrasková M; Forejt J; Szabo M; Pádr R
    Nephrol Dial Transplant; 2008 May; 23(5):1776-7; author reply 1777-8. PubMed ID: 18283090
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
    Frazão JM; Adragão T
    Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARACEST agents: modulating MRI contrast via water proton exchange.
    Zhang S; Merritt M; Woessner DE; Lenkinski RE; Sherry AD
    Acc Chem Res; 2003 Oct; 36(10):783-90. PubMed ID: 14567712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate.
    Samy R; Faustino PJ; Adams W; Yu L; Khan MA; Yang Y
    J Pharm Biomed Anal; 2010 Apr; 51(5):1108-12. PubMed ID: 20031362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
    Yang Y; Bykadi S; Carlin AS; Shah RB; Yu LX; Khan MA
    J Pharm Sci; 2013 Apr; 102(4):1370-81. PubMed ID: 23334989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
    Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
    J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphate binder up to date].
    Shigematsu T; Sakaguchi T; Orita H
    Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.